$Day One Biopharmaceuticals(DAWN.US$
根据 FIREFLY-1 第二阶段的读数,$DAWN 于 2024 年 4 月 30 日获得了 PDUFA 的优先审核。同时,$DAWN在获得批准后获得了优先审查凭证(PRV)。据报道,它的卖出价格从6700万美元到3.5亿美元不等,获得批准后将带来巨大的增值。
托伏拉非尼是正在评估的候选药物。它是一种 II 型 RAF 抑制剂,靶向突变和融合 BRAF 改变。这种 pan-RAF 抑制剂优于...
根据 FIREFLY-1 第二阶段的读数,$DAWN 于 2024 年 4 月 30 日获得了 PDUFA 的优先审核。同时,$DAWN在获得批准后获得了优先审查凭证(PRV)。据报道,它的卖出价格从6700万美元到3.5亿美元不等,获得批准后将带来巨大的增值。
托伏拉非尼是正在评估的候选药物。它是一种 II 型 RAF 抑制剂,靶向突变和融合 BRAF 改变。这种 pan-RAF 抑制剂优于...
已翻译
$杰龙(GERN.US$
IMO the phase III result published in the Lancet is not impressive.
1. 40% reaching endpoint versus 15% receiving placebo (doubtful here)
2. 91% Grade 3-4 TEAE, compared to ESA and luspatercept (current standard of care) is insane
3. Even approved, very limited population of patients willing to take
IMO the phase III result published in the Lancet is not impressive.
1. 40% reaching endpoint versus 15% receiving placebo (doubtful here)
2. 91% Grade 3-4 TEAE, compared to ESA and luspatercept (current standard of care) is insane
3. Even approved, very limited population of patients willing to take
1
$Iovance Biotherapeutics(IOVA.US$ Weird price movement after FDA approval
2
1
$NRX Pharmaceuticals(NRXP.US$
1.NRX100:
治疗急性自杀的静脉氯胺酮于2024年申请加速批准(需要估计)仅供参考:Janssen批准并以SPRAVATO® 的名义出售鼻用氯胺酮。在这里,詹森使用了一种名为埃西胺酮的手性氯胺酮异构体来治疗抑郁症
计划分拆和条款表已准备就绪
350万名目标患者;
配方是独一无二的(浓度和改变以限制滥用)为护理人员提供一种更合法的氯胺酮处方方式...
1.NRX100:
治疗急性自杀的静脉氯胺酮于2024年申请加速批准(需要估计)仅供参考:Janssen批准并以SPRAVATO® 的名义出售鼻用氯胺酮。在这里,詹森使用了一种名为埃西胺酮的手性氯胺酮异构体来治疗抑郁症
计划分拆和条款表已准备就绪
350万名目标患者;
配方是独一无二的(浓度和改变以限制滥用)为护理人员提供一种更合法的氯胺酮处方方式...
已翻译
$Iovance Biotherapeutics(IOVA.US$ Target 2x?
1
$Iovance Biotherapeutics(IOVA.US$ 哎哟... 昨天才多了 😭 应该等今天的讨价还价。
已翻译
1
6
$Iovance Biotherapeutics(IOVA.US$
Tumor infiltrating lymphocytes(TILs) cell therapy will see the transfomation from benchside to bedside after ~30 years of dedicated academic and industrial efforts!
1. Why TILs cell therapy has a high likelihood of getting a nod from FDA?
In this field, Iovance and the Netherlands Cancer Research are at the forefront of TILs development, both with a primary focus on advanced melanoma—a substantial market characterized by unm...
Tumor infiltrating lymphocytes(TILs) cell therapy will see the transfomation from benchside to bedside after ~30 years of dedicated academic and industrial efforts!
1. Why TILs cell therapy has a high likelihood of getting a nod from FDA?
In this field, Iovance and the Netherlands Cancer Research are at the forefront of TILs development, both with a primary focus on advanced melanoma—a substantial market characterized by unm...
4
1
$哔哩哔哩(BILI.US$ In my opinion, the sell point for this company is Chinese Youtube. However, people seem to view it as a game company. Admittedly, game revenue make up a portion, and this, at best, serves as a complimentary branch of operations.
1